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Huntington’s disease (HD) age of onset (AO) is mainly determined by the length of the CAG
repeat expansion in the huntingtin gene. The remaining AO variability has been attributed to
other little-known factors. A factor that has been associated with other neurodegenerative
diseases is arterial hypertension (AHT). The aim of this study is to evaluate the contribution
of AHT to the AO of HD. We used data from a cohort of 630 European HD patients with adult
onset collected by the REGISTRY project of the European Huntington’s Disease Network.
Multiple linear regression and ANOVA, controlling for the CAG repeat number of the
expanded allele (CAGexp) of each patient, were performed to assess the association
between the AHT condition and the AO of the motor symptoms (mAO). The results showed
a significant association between AHT and mAO, especially when we only considered the
patients diagnosed with AHT prior to manifesting any HD signs (pre-HD AHT). Remarkably,
despite the low number of cases, those patients developed motor symptoms 5–8 years later
than normotensive patients in the most frequent CAGexp range (40–44). AHT is an age-
related condition and consequently, the age of the patient at the time of data collection could
be a confounder variable. However, given that most pre-HD AHT patients included in our
study had started treatment with antihypertensive drugs prior to the onset of HD, and that
antihypertensive drugs have been suggested to confer a neuroprotective effect in other
neurodegenerative diseases, raises the interest in elucidating the impact of AHT and/or
AHT treatment in HD age of onset in further studies. A confirmation of our results in a larger
sample set would open the possibility to significantly improve HD management.
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Introduction
Huntington’s disease (OMIM: 143100) AO is mainly (about 60%) determined by the length of
the CAG repeat expansion (CAGexp) in the HTT gene. The remaining variability has been
attributed to genetic and little-explored environmental factors [1]. Arterial Hypertension
(AHT) is a risk factor for numerous diseases with controversial effect on neurodegenerative
diseases [2]. The impact of AHT on HD has not been examined to date. The aim of this study
was to explore whether AHT could be an AO modifier factor for HD.
Methods
European Huntington’s Disease Network’s (EHDN) REGISTRY project provided data on
1,011 HD individuals. For this study, we gathered information on mAO [3], sex and age at the
time of data collection of 630 European adult-onset HD patients with CAGexp ranging
between 40 and 50, with known AHT status (86 hypertensives vs. 544 normotensives) and with
AHT onset date available in the REGISTRY dataset. The 40–50 CAGexp range was selected to
avoid the inclusion of juvenile-onset HD cases and thus, the introduction of errors in the
regression analysis [3–5]. Furthermore, 40–50 CAGexp was the repeat range of hypertensive
patients in our sample. Consequently, comparisons were performed between hypertensives
and normotensives exhibiting equivalent CAGexp distribution. Ethical approval and written
informed consents for each participant were obtained by the EHDN from the local ethics com-
mittees (http://www.euro-hd.net/html/registry), in compliance with the Declaration of Hel-
sinki, the International Conference on Harmonisation—Good Clinical Practice (CH-GCP),
and local regulations. Specific ethical approval of the study was obtained from the Clinical
Research Ethics Committee of the Basque Country (CEIC- Euskadi), the Human Research
Ethics Committee of the University of the Basque Country (CEISH) and the EHDN Scientific
Bioethical Advisory Committee (SBAC). Multiple linear regression and ANCOVA tests were
used to analyze the relationship between mAO and AHT, using CAGexp value as a covariate
in each regression. Kolmogorov-Smirnov (K-S) test was used to compare CAGexp and mAO
distributions between normotensive and hypertensive patients, while Mann-Whitney U test
was used, in the same way, to compare the medians(SPSS ver.23.0; SPSS Inc.).
Results
In patients with CAGexp ranging between 40 and 50, AHT explains HD mAO variability sig-
nificantly (regression analysis P = 0.016, Table 1; ANCOVA test P = 0.004). Remarkably, mAO
in HD patients with AHT was manifested on average 7 years later than in normotensives (52.5
vs. 45 years, P<0.0001), suggesting that AHT is associated with the appearance of motor symp-
toms at a later age. A significant association between AHT and a higher mAO was still detected
in patients who manifested AHT before HD symptoms (pre-HD AHT patients) (P = 0.024,
Table 1). Despite the limited number of patients (N = 28), we detected that the mAO median
value was 10 years higher in pre-HD AHT patients than in normotensive patients.
Differences in CAGexp distribution among pre-HD AHT and normotensive patients were
detected (K-S test P<0.0001), probably due to sample size differences. Thus, we focused on
HD patients carrying the most frequent CAGexp alleles (ranging from 40 to 44). In this case,
the CAGexp allele distribution did not now differ between hypertensives and normotensives
(P = 0.266, K-S test). However, the association between AHT and mAO (P = 0.020, Table 1)
and the differences in the mAO distribution (P = 0.011, K-S test) remained significant.
Remarkably, pre-HD AHT developed motor symptoms 6 years later than normotensives on
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average (56 vs. 50 years, P = 0.002). Interestingly, the tendency of pre-HD AHT patients to
manifest HD at higher mAOs relative to normotensives was detected for each CAGexp repeat
number, except for the 41 CAGexp allele and the median difference ranged between 5 and 8
years (Fig 1).
Discussion
AHT, the most prevalent cardiovascular disorder in developed countries, has been associated
with neuronal disorders such as Parkinson’disease (PD) and Alzheimer’s disease (AD) [6–8],
suggesting that it may affect the neurodegeneration process. Our study is the first exploring
the impact of AHT on HD and the first revealing an association between AHT and mAO.
According to our results, patients with AHT show the HD symptoms later (median of 7.5
years) than normotensive patients. These differences are more evident (median of 10.5 years)
in the analysis that only takes into account patients that exhibited AHT before HD onset (pre-
HD AHT patients). The results of the pre-HD AHT individuals are particularly relevant, since
having manifested AHT before HD onset is a requeriment for the examined variable to be con-
sidered a mAO modifying factor. The results after normalization of ratings to CAGexp values
between 40 to 44 in pre-HD AHT and in normotensive patients indicate that the pre-HD AHT
patients show motor symptoms between 5 and 8 years later than normotensive patients with
the same CAGexp, suggesting that AHT may be an AO modifier. This effect is remarkably lon-
ger than those reported for any genetic modifier in HD [9].
The mechanism underlying this observation is presently unknown. In fact, although AHT
has been related with other neurodegenerative diseases, its effect is presently unclear. AHT has
been associated with a reduced risk of Parkinson’s disease [6], but has also been considered a
risk factor [7]. In AD, the relationship is also controversial [2], but most of the reviewed litera-
ture has noted that AHT is a strong risk factor [8], while antihypertensive drugs reduce the
risk of AD [8,10]. Interestingly, most pre-HD AHT patients included in this study had started
treatment with antihypertensive drugs prior to the onset of HD. Antihypertensive drugs have
been suggested to confer a neuroprotective effect not only in AD [8,10], but also in PD [11],
and they might also play a role in the later mAO shown by HD patients in our study.
The mechanism underlying this observation is presently unknown. In fact, although AHT
has been related with other neurodegenerative diseases, its effect is presently unclear. AHT has
been associated with a reduced risk of Parkinson’s disease [6] but has also been considered a
risk factor [7]. In AD, the relationship is also controversial [2], but most of the reviewed litera-
ture has noted that AHT is a strong risk factor [8] while antihypertensive drugs reduce the risk
of AD [8,10]. Interestingly, most pre-HD AHT patients included in this study had started
treatment with antihypertensive drugs prior to the onset of HD. Antihypertensive drugs have
Table 1. Multiple regression analyses and descriptive statistics for mAO.
Model N Adjusted R2 P-value Groups N Motor AO




HTT CAGexp + AHT (40–50 CAGexp range) 630 0.592 0.016 With AHT 86 52.5 <0.0001 <0.0001
Normotensive 544 45
HTT CAGexp + Pre-HD AHT (40–50 CAGexp
range)
572 0.604 0.024 Pre-HD AHT 28 55.5 <0.0001 <0.0001
Normotensive 544 45
HTT CAGexp + Pre-HD AHT (40–44 CAGexp
range)
384 0.340 0.020 Pre-HD AHT 27 56 0.002 0.011
Normotensive 357 50
https://doi.org/10.1371/journal.pone.0197975.t001
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been suggested to confer a neuroprotective effect, not only in AD [8,10], but also in PD [11],
and they might also play a role in the later mAO shown by HD patients in our study.
Unfortunately, the high variability in the antihypertensive treatment types, changes in med-
ication and incomplete medical records of our HD patient cohort have hampered our under-
standing of the impact of antihypertensive drugs in HD mAO. An additional limitation is that
the prevalence of AHT increases with age [12], which means that a later onset HD patient is
more likely to be recorded with a history of AHT, than an earlier onset participant. We have
observed that the age of the participant at the time of data collection is correlated with mAO,
as well as, with AHT. Thus, although age does not explain the mAO variability, it could have
an influence in the observed relationship between mAO and AHT, leading to a spureous
Fig 1. Variance in mAO for each CAGexp allele (40–44 range) in normotensives and in pre-HD AHT patients. Numbers above the square brackets are the
difference in median years between Pre-HD AHT and normotensives for each CAGexp allele.
https://doi.org/10.1371/journal.pone.0197975.g001
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association. On the other hand, the mAO and AHT onset data suggest that the pre-HD AHT
condition is not necessarily related to later onset ages: 1) the median age of AHT onset in pre-
HD AHT cases is 45.5 years, which is similar to the mAO median in normotensives patients
(45 years); 2) the majority of pre-HD AHT patients (71%) showed motor symptoms at< 60
years and there were no pre-HD AHT cases with late-onset mAO (>70 years); 3) the effect of
AHT in mAO is detected in ranges of CAG (40–44) in which juvenil and late HD cases
(extreme cases that could bias the result) are not manifested. Notwithstanding this evidence,
we cannot rule out the possible influence that age of patients at the time of data collection
could have on the pre-HD AHT condition and, consequently, on the observed association.
In spite of the caveats, given the lack of current treatment options for HD, we consider that
the findings of our study merits to be reported considering the accessibility to AHT treatments
and the potential impact of these drugs (or the AHT condition) in the onset of HD. We believe
that the role of AHT and/or its treatment should be further examined in other HD cohorts
such as ENROLL-HD and possibly in pre-clinical models.
Supporting information
S1 Dataset. 630 European adult-onset HD patient dataset. Age: patient’s age at the time of
data collection; Sex: M (male) and F (female); CAGexp: CAG number repeat in expanded
allele; mAO: motor onset, age of the first motor symptoms; AHT condition: normotensive
(patient without arterial hypertension record), with AHT (patient with arterial hypertension
records) and pre-HD AHT (patient with arterial hypertension records who manifested hyper-
tension before HD symptoms).
(PDF)
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Angers (Centre de référence des maladies neurogénétique- CHU d’Angers): Philippe Allain,
Dominique Bonneau, Marie Bost, Bénédicte Gohier, Marie-Anne Guérid, Audrey Olivier,
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(Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie):
Kai Boelmans, Christos Ganos, Walburgis Heinicke, Ute Hidding, Jan Lewerenz, Alexan-
der Münchau, Michael Orth, Jenny Schmalfeld, Lars Stubbe, Simone Zittel; Hannover
(Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule
Hannover): Gabriele Diercks, Dirk Dressler, Flverly Francis, Sabine Gayde-Stephan,
Heike Gorzolla, Bianca Kramer, Rebecca Minschke, Christoph Schrader, Pawel Tacik;
Itzehoe (Schwerpunktpraxis Huntington, Neurologie und Psychiatrie): Michael Rib-
bat; München (Huntington-Ambulanz im Neuro-Kopfzentrum—Klinikum rechts der
Isar der Neurologischen Klinik und Poliklinik der Technischen Universität Mün-
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